JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article

J Thorac Cardiovasc Surg 2006;132:1362
© 2006 The American Association for Thoracic Surgery

General Thoracic Surgery

Discussion

The first 20% of the full text of this article appears below.

Dr David R. Jones (Charlottesville, Va). I congratulate you on a nice presentation.

You hypothesized that gossypol would enhance Apo2L and TRAIL-mediated apoptosis through its ability to inhibit Bcl2 and perhaps BclXL. Do you have any evidence that this is indeed the pathway? For instance, have you performed any siRNA experiments with either Bcl2 or BclXL that would be more confirmatory of your hypothesis?

Second, gossypol has been shown to increase both Fas and Fas . . . [Full Text of this Article]


Related Article

Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor–related apoptosis-inducing ligand
Wen-Shuz Yeow, Aris Baras, Alex Chua, Duc M. Nguyen, Shailen S. Sehgal, David S. Schrump, and Dao M. Nguyen
J. Thorac. Cardiovasc. Surg. 2006 132: 1356-1362. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2006 by The American Association for Thoracic Surgery.